| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.046 | 0.4 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.4 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.4 |